KEGG   DRUG: Trastuzumab
Entry
D03257                      Drug                                   
Name
Trastuzumab (USAN/INN);
Trastuzumab (genetical recombination) (JAN);
Trastuzumab (genetical recombination) [Trastuzumab biosimilar 1] (JAN);
Trastuzumab (genetical recombination) [Trastuzumab biosimilar 2] (JAN);
Trastuzumab (genetical recombination) [Trastuzumab biosimilar 3] (JAN);
Trastuzumab-pkrb;
Trastuzumab-anns;
Trastuzumab-dkst;
Trastuzumab-dttb;
Trastuzumab-qyyp;
Trastuzumab-anns;
Herceptin (TN);
Herzuma (TN);
Kanjinti (TN);
Ogivri (TN);
Ontruzant (TN)
Product
Sequence
(Heavy chain)
EVQLVESGGG LVQPGGSLRL SCAASGFNIK DTYIHWVRQA PGKGLEWVAR IYPTNGYTRY
ADSVKGRFTI SADTSKNTAY LQMNSLRAED TAVYYCSRWG GDGFYAMDYW GQGTLVTVSS
ASTKGPSVFP LAPSSKSTSG GTAALGCLVK DYFPEPVTVS WNSGALTSGV HTFPAVLQSS
GLYSLSSVVT VPSSSLGTQT YICNVNHKPS NTKVDKKVEP KSCDKTHTCP PCPAPELLGG
PSVFLFPPKP KDTLMISRTP EVTCVVVDVS HEDPEVKFNW YVDGVEVHNA KTKPREEQYN
STYRVVSVLT VLHQDWLNGK EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ VYTLPPSREE
MTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV LDSDGSFFLY SKLTVDKSRW
QQGNVFSCSV MHEALHNHYT QKSLSLSPG
(Light chain)
DIQMTQSPSS LSASVGDRVT ITCRASQDVN TAVAWYQQKP GKAPKLLIYS ASFLYSGVPS
RFSGSRSGTD FTLTISSLQP EDFATYYCQQ HYTTPPTFGQ GTKVEIKRTV AAPSVFIFPP
SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT
LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC
(Disulfide bridge: H22-H96, H147-H203, H264-H324, H370-H428, H229-H'229, H232-H'232, L23-L88, L134-L194, H223-L214)
  Type
Peptide
Class
Antineoplastic
 DG01918  Tyrosine kinase inhibitor
  DG01917  Receptor tyrosine kinase inhibitor
   DG03158  HER2 inhibitor
Remark
Therapeutic category: 4291
ATC code: L01FD01
Product: D03257<JP/US>
Product (mixture): D11560<US> D11934<JP/US>
Efficacy
Antineoplastic, Receptor tyrosine kinase inhibitor, Anti-HER2 antibody
  Disease
Breast cancer (HER2 overexpressing) [DS:H00031]
Gastric cancer (HER2 overexpressing) [DS:H00018]
  Type
Monoclonal antibody
Target
ERBB2* (HER2, CD340) [HSA_VAR:2064v1] [HSA:2064] [KO:K05083]
  Pathway
hsa04012  ErbB signaling pathway
hsa05200  Pathways in cancer
hsa05224  Breast cancer
hsa05226  Gastric cancer
  Network
nt06270  Breast cancer
Interaction
Structure map
map07045  Antineoplastics - protein kinase inhibitors
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L01 ANTINEOPLASTIC AGENTS
   L01F MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
    L01FD HER2 (Human Epidermal Growth Factor Receptor 2) inhibitors
     L01FD01 Trastuzumab
      D03257  Trastuzumab (USAN/INN) <JP/US>
USP drug classification [BR:br08302]
 Antineoplastics
  Monoclonal Antibody/Antibody-Drug Conjugate
   Trastuzumab
    D03257  Trastuzumab (USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
 4  Agents affecting cellular function
  42  Antineoplastics
   429  Miscellaneous
    4291  Other Antitumors
     D03257  Trastuzumab (USAN/INN); Trastuzumab (genetical recombination) (JAN); Trastuzumab (genetical recombination) [Trastuzumab biosimilar 1] (JAN); Trastuzumab (genetical recombination) [Trastuzumab biosimilar 2] (JAN); Trastuzumab (genetical recombination) [Trastuzumab biosimilar 3] (JAN)
Drug groups [BR:br08330]
 Antineoplastic
  DG01918  Tyrosine kinase inhibitor
   DG01917  Receptor tyrosine kinase inhibitor
    DG03158  HER2 inhibitor
     D03257  Trastuzumab
Drug classes [BR:br08332]
 Antineoplastic
  DG03158  HER2 inhibitor
   D03257  Trastuzumab
Target-based classification of drugs [BR:br08310]
 Protein kinases
  Receptor tyrosine kinases (RTK)
   EGFR family
    ERBB2* (HER2, CD340) [HSA_VAR:2064v1]
     D03257  Trastuzumab (USAN/INN) <JP/US>
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D03257
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D03257
Pharmacogenomic biomarkers [br08341.html]
 Somatic variations in targeted cancer therapies
  D03257
Other DBs
CAS: 180288-69-1
PubChem: 17397410
NIKKAJI: J2.044.149F
LinkDB

» Japanese version   » Back

KEGG   DRUG: Trastuzumab emtansine
Entry
D09980                      Drug                                   
Name
Trastuzumab emtansine (USAN/INN);
Trastuzumab emtansine (genetical recombination) (JAN);
Ado-trastuzumab emtansine;
Kadcyla (TN)
Product
Formula
C6448H9948N1720O2012S44
Exact mass
145075.67
Mol weight
145165.1575
Class
Antineoplastic
 DG01918  Tyrosine kinase inhibitor
  DG01917  Receptor tyrosine kinase inhibitor
   DG03158  HER2 inhibitor
Remark
Therapeutic category: 4291
ATC code: L01FD03
Product: D09980<JP/US>
Efficacy
Antineoplastic, Tubulin polymerization inhibitor, Receptor tyrosine kinase inhibitor, Anti-HER2 antibody
  Disease
Breast cancer (HER2 positive) [DS:H00031]
  Type
Antibody-drug conjugate
Target
ERBB2* (HER2, CD340) [HSA_VAR:2064v1 2064v3] [HSA:2064] [KO:K05083]
TUBB [HSA:10381 10382 10383 203068 347688 347733 7280 81027 84617] [KO:K07375]
  Pathway
hsa04012  ErbB signaling pathway
hsa05200  Pathways in cancer
hsa05224  Breast cancer
  Network
nt06270  Breast cancer
Interaction
Structure map
map07045  Antineoplastics - protein kinase inhibitors
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L01 ANTINEOPLASTIC AGENTS
   L01F MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
    L01FD HER2 (Human Epidermal Growth Factor Receptor 2) inhibitors
     L01FD03 Trastuzumab emtansine
      D09980  Trastuzumab emtansine (USAN/INN) <JP/US>
USP drug classification [BR:br08302]
 Antineoplastics
  Monoclonal Antibody/Antibody-Drug Conjugate
   Ado-Trastuzumab Emtansine
    D09980  Trastuzumab emtansine (USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
 4  Agents affecting cellular function
  42  Antineoplastics
   429  Miscellaneous
    4291  Other Antitumors
     D09980  Trastuzumab emtansine (USAN/INN); Trastuzumab emtansine (genetical recombination) (JAN)
Drug groups [BR:br08330]
 Antineoplastic
  DG01918  Tyrosine kinase inhibitor
   DG01917  Receptor tyrosine kinase inhibitor
    DG03158  HER2 inhibitor
     D09980  Trastuzumab emtansine
Drug classes [BR:br08332]
 Antineoplastic
  DG03158  HER2 inhibitor
   D09980  Trastuzumab emtansine
Target-based classification of drugs [BR:br08310]
 Protein kinases
  Receptor tyrosine kinases (RTK)
   EGFR family
    ERBB2* (HER2, CD340) [HSA_VAR:2064v1 2064v3]
     D09980  Trastuzumab emtansine (USAN/INN) <JP/US>
 Not elsewhere classified
  Cellular process
   Cytoskeleton
    TUBB
     D09980  Trastuzumab emtansine (USAN/INN) <JP/US>
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D09980
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D09980
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D09980
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D09980
Pharmacogenomic biomarkers [br08341.html]
 Somatic variations in targeted cancer therapies
  D09980
Other DBs
CAS: 1018448-65-1
PubChem: 135626701
LinkDB

» Japanese version   » Back

KEGG   DRUG: Pertuzumab
Entry
D05446                      Drug                                   
Name
Pertuzumab (USAN/INN);
Pertuzumab (genetical recombination) (JAN);
Perjeta (TN)
Product
Class
Antineoplastic
 DG01918  Tyrosine kinase inhibitor
  DG01917  Receptor tyrosine kinase inhibitor
   DG03158  HER2 inhibitor
Remark
Therapeutic category: 4291
ATC code: L01FD02
Product: D05446<JP/US>
Product (mixture): D11934<JP/US>
Efficacy
Antineoplastic, Receptor tyrosine kinase inhibitor, Anti-HER2 antibody
  Disease
Breast cancer (HER2 positive) [DS:H00031]
  Type
Monoclonal antibody
Target
ERBB2* (HER2, CD340) [HSA_VAR:2064v1 2064v3] [HSA:2064] [KO:K05083]
  Pathway
hsa04012  ErbB signaling pathway
hsa05200  Pathways in cancer
hsa05224  Breast cancer
  Network
nt06270  Breast cancer
Interaction
Structure map
map07045  Antineoplastics - protein kinase inhibitors
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L01 ANTINEOPLASTIC AGENTS
   L01F MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
    L01FD HER2 (Human Epidermal Growth Factor Receptor 2) inhibitors
     L01FD02 Pertuzumab
      D05446  Pertuzumab (USAN/INN) <JP/US>
USP drug classification [BR:br08302]
 Antineoplastics
  Monoclonal Antibody/Antibody-Drug Conjugate
   Pertuzumab
    D05446  Pertuzumab (USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
 4  Agents affecting cellular function
  42  Antineoplastics
   429  Miscellaneous
    4291  Other Antitumors
     D05446  Pertuzumab (USAN/INN); Pertuzumab (genetical recombination) (JAN)
Drug groups [BR:br08330]
 Antineoplastic
  DG01918  Tyrosine kinase inhibitor
   DG01917  Receptor tyrosine kinase inhibitor
    DG03158  HER2 inhibitor
     D05446  Pertuzumab
Drug classes [BR:br08332]
 Antineoplastic
  DG03158  HER2 inhibitor
   D05446  Pertuzumab
Target-based classification of drugs [BR:br08310]
 Protein kinases
  Receptor tyrosine kinases (RTK)
   EGFR family
    ERBB2* (HER2, CD340) [HSA_VAR:2064v1 2064v3]
     D05446  Pertuzumab (USAN/INN) <JP/US>
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D05446
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D05446
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D05446
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D05446
Pharmacogenomic biomarkers [br08341.html]
 Somatic variations in targeted cancer therapies
  D05446
Other DBs
CAS: 380610-27-5
PubChem: 47207115
LinkDB

» Japanese version   » Back

KEGG   DRUG: Lapatinib ditosylate
Entry
D04024                      Drug                                   
Name
Lapatinib ditosylate (USAN);
Lapatinib tosilate hydrate (JAN);
Lapatinib ditosylate monohydrate;
Tykerb (TN);
Tyverb (TN)
Product
  Generic
Formula
C29H26ClFN4O4S. (C7H8O3S)2. H2O
Exact mass
942.1841
Mol weight
943.4761
Structure
Class
Antineoplastic
 DG01918  Tyrosine kinase inhibitor
  DG01917  Receptor tyrosine kinase inhibitor
   DG03158  HER2 inhibitor
Metabolizing enzyme substrate
 DG02918  CYP2C8 substrate
 DG01639  CYP2C19 substrate
 DG01633  CYP3A/CYP3A4 substrate
  DG02913  CYP3A4 substrate
 DG02925  CYP3A5 substrate
Transporter substrate
 DG01665  ABCB1 substrate
 DG01913  ABCG2 substrate
Remark
Therapeutic category: 4291
ATC code: L01EH01
Chemical structure group: DG00715
Product (DG00715): D04024<JP/US>
Efficacy
Antineoplastic, Receptor tyrosine kinase inhibitor
  Disease
Breast cancer (HER2 overexpressing) [DS:H00031]
Target
EGFR [HSA:1956] [KO:K04361]
ERBB2* (HER2, CD340) [HSA_VAR:2064v1] [HSA:2064] [KO:K05083]
  Pathway
hsa04010  MAPK signaling pathway
hsa04012  ErbB signaling pathway
hsa05200  Pathways in cancer
hsa05224  Breast cancer
  Network
nt06270  Breast cancer
Metabolism
Enzyme: CYP3A4 [HSA:1576], CYP3A5 [HSA:1577]; CYP2C19 [HSA:1557], CYP2C8 [HSA:1558]
Transporter: ABCB1 [HSA:5243], ABCG2 [HSA:9429]
Interaction
Structure map
map07045  Antineoplastics - protein kinase inhibitors
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L01 ANTINEOPLASTIC AGENTS
   L01E PROTEIN KINASE INHIBITORS
    L01EH Human epidermal growth factor receptor 2 (HER2) tyrosine kinase inhibitors
     L01EH01 Lapatinib
      D04024  Lapatinib ditosylate (USAN) <JP/US>
USP drug classification [BR:br08302]
 Antineoplastics
  Molecular Target Inhibitors
   Lapatinib
    D04024  Lapatinib ditosylate (USAN)
Therapeutic category of drugs in Japan [BR:br08301]
 4  Agents affecting cellular function
  42  Antineoplastics
   429  Miscellaneous
    4291  Other Antitumors
     D04024  Lapatinib ditosylate (USAN); Lapatinib tosilate hydrate (JAN)
Drug groups [BR:br08330]
 Antineoplastic
  DG01918  Tyrosine kinase inhibitor
   DG01917  Receptor tyrosine kinase inhibitor
    DG03158  HER2 inhibitor
     DG00715  Lapatinib
      D04024  Lapatinib ditosylate
 Metabolizing enzyme substrate
  DG02918  CYP2C8 substrate
   DG00715  Lapatinib
    D04024  Lapatinib ditosylate
  DG01639  CYP2C19 substrate
   DG00715  Lapatinib
    D04024  Lapatinib ditosylate
  DG01633  CYP3A/CYP3A4 substrate
   DG02913  CYP3A4 substrate
    DG00715  Lapatinib
     D04024  Lapatinib ditosylate
  DG02925  CYP3A5 substrate
   DG00715  Lapatinib
    D04024  Lapatinib ditosylate
 Transporter substrate
  DG01665  ABCB1 substrate
   DG00715  Lapatinib
    D04024  Lapatinib ditosylate
  DG01913  ABCG2 substrate
   DG00715  Lapatinib
    D04024  Lapatinib ditosylate
Drug classes [BR:br08332]
 Antineoplastic
  DG03158  HER2 inhibitor
   D04024  Lapatinib ditosylate
Target-based classification of drugs [BR:br08310]
 Protein kinases
  Receptor tyrosine kinases (RTK)
   EGFR family
    EGFR
     D04024  Lapatinib ditosylate (USAN) <JP/US>
    ERBB2* (HER2, CD340) [HSA_VAR:2064v1]
     D04024  Lapatinib ditosylate (USAN) <JP/US>
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D04024
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D04024
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D04024
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D04024
Drug metabolizing enzymes and transporters [br08309.html]
 Drug metabolizing enzymes
  D04024
 Drug transporters
  D04024
Pharmacogenomic biomarkers [br08341.html]
 Somatic variations in targeted cancer therapies
  D04024
 Polymorphisms and mutations affecting drug response
  D04024
Drug groups [BR:br08330]
 Antineoplastic
  DG01918  Tyrosine kinase inhibitor
   DG01917  Receptor tyrosine kinase inhibitor
    DG03158  HER2 inhibitor
     DG00715  Lapatinib
 Metabolizing enzyme substrate
  DG02918  CYP2C8 substrate
   DG00715  Lapatinib
  DG01639  CYP2C19 substrate
   DG00715  Lapatinib
  DG01633  CYP3A/CYP3A4 substrate
   DG02913  CYP3A4 substrate
    DG00715  Lapatinib
  DG02925  CYP3A5 substrate
   DG00715  Lapatinib
 Transporter substrate
  DG01665  ABCB1 substrate
   DG00715  Lapatinib
  DG01913  ABCG2 substrate
   DG00715  Lapatinib
Other DBs
CAS: 388082-78-8
PubChem: 17398008
ChEBI: 192581
LigandBox: D04024
LinkDB
KCF data

ATOM        63
            1   O0  O    35.3225  -20.0361
            2   C8x C    19.9641  -13.5924
            3   N5x N    19.9641  -14.9937
            4   C8y C    21.1552  -15.6944
            5   C8y C    22.4164  -14.9937
            6   C8y C    22.4164  -13.5924
            7   N5x N    21.1552  -12.8917
            8   C8x C    23.6075  -15.6944
            9   C8y C    24.7987  -14.9937
            10  C8x C    24.7987  -13.5924
            11  C8x C    23.6075  -12.8917
            12  N1b N    21.1552  -17.0957
            13  C8y C    22.3464  -17.7964
            14  C8x C    22.3464  -19.1977
            15  C8y C    23.6075  -19.8983
            16  C8y C    24.7987  -19.1977
            17  C8x C    24.7987  -17.7964
            18  C8x C    23.6075  -17.0957
            19  X   Cl   23.6075  -21.2997
            20  O2a O    25.9898  -19.8983
            21  C1b C    27.1809  -19.1977
            22  C8y C    28.3720  -19.8983
            23  C8x C    28.3720  -21.2997
            24  C8x C    29.6332  -22.0003
            25  C8x C    30.8244  -21.2997
            26  C8y C    30.8244  -19.8983
            27  C8x C    29.6332  -19.1977
            28  X   F    32.0155  -19.1977
            29  C8y C    25.9898  -15.6944
            30  C8x C    26.4102  -17.0256
            31  C8x C    27.8115  -17.0256
            32  C8y C    28.2319  -15.6944
            33  O2x O    27.1109  -14.8536
            34  C1b C    29.4455  -14.9937
            35  N1b N    30.6591  -15.6944
            36  C1b C    31.8727  -14.9937
            37  C1b C    33.0862  -15.6944
            38  S4a S    34.2999  -14.9937
            39  C1a C    35.5134  -15.6944
            40  O1d O    35.2907  -14.0029
            41  O1d O    33.3089  -14.0029
            42  C8x C    38.4645  -17.4460
            43  C8x C    38.4645  -18.8473
            44  C8y C    39.6780  -19.5480
            45  C8x C    40.8917  -18.8473
            46  C8x C    40.8917  -17.4460
            47  C8y C    39.6780  -16.7454
            48  C1a C    39.6780  -20.9491
            49  S4a S    39.6780  -15.3442
            50  O1d O    39.6780  -13.9429
            51  O1d O    41.0794  -15.3442
            52  O1d O    38.2767  -15.3442
            53  C8x C    38.4645  -17.4460
            54  C8x C    38.4645  -18.8473
            55  C8y C    39.6780  -19.5480
            56  C8x C    40.8917  -18.8473
            57  C8x C    40.8917  -17.4460
            58  C8y C    39.6780  -16.7454
            59  S4a S    39.6780  -15.3442
            60  O1d O    39.6780  -13.9429
            61  O1d O    41.0794  -15.3442
            62  O1d O    38.2767  -15.3442
            63  C1a C    39.6780  -20.9491
BOND        66
            1     2   3 1
            2     3   4 2
            3     4   5 1
            4     5   6 1
            5     6   7 1
            6     2   7 2
            7     5   8 2
            8     8   9 1
            9     9  10 2
            10   10  11 1
            11    6  11 2
            12    4  12 1
            13   12  13 1
            14   13  14 2
            15   14  15 1
            16   15  16 2
            17   16  17 1
            18   17  18 2
            19   13  18 1
            20   15  19 1
            21   16  20 1
            22   20  21 1
            23   21  22 1
            24   22  23 2
            25   23  24 1
            26   24  25 2
            27   25  26 1
            28   26  27 2
            29   22  27 1
            30   26  28 1
            31    9  29 1
            32   30  31 1
            33   31  32 2
            34   32  33 1
            35   33  29 1
            36   30  29 2
            37   32  34 1
            38   34  35 1
            39   35  36 1
            40   36  37 1
            41   37  38 1
            42   38  39 1
            43   38  40 2
            44   38  41 2
            45   42  43 2
            46   43  44 1
            47   44  45 2
            48   45  46 1
            49   46  47 2
            50   42  47 1
            51   44  48 1
            52   47  49 1
            53   49  50 1
            54   49  51 2
            55   49  52 2
            56   53  54 2
            57   54  55 1
            58   55  56 2
            59   56  57 1
            60   57  58 2
            61   53  58 1
            62   55  63 1
            63   58  59 1
            64   59  60 1
            65   59  61 2
            66   59  62 2
BRACKET     1    37.6600  -21.8400   37.6600  -13.1600
            1    41.9300  -13.1600   41.9300  -21.8400
            1  2
 ORIGINAL  1   42  43  44  45  46  47  49  50  51  52  48
 REPEAT    1   53  54  55  56  57  58  59  60  61  62  63

» Japanese version   » Back

KEGG   DRUG: Neratinib maleate
Entry
D10898                      Drug                                   
Name
Neratinib maleate;
Nerlynx (TN)
Product
Formula
C30H29ClN6O3. C4H4O4
Exact mass
672.2099
Mol weight
673.1148
Structure
Simcomp
Class
Antineoplastic
 DG01918  Tyrosine kinase inhibitor
  DG01917  Receptor tyrosine kinase inhibitor
   DG03158  HER2 inhibitor
Remark
ATC code: L01EH02
Chemical structure group: DG02303
Product (DG02303): D10898<US>
Efficacy
Antineoplastic, Receptor tyrosine kinase inhibitor
  Disease
Breast cancer (HER2 positive) [DS:H00031]
Target
EGFR [HSA:1956] [KO:K04361]
ERBB2* (HER2, CD340) [HSA_VAR:2064v1 2064v3] [HSA:2064] [KO:K05083]
ERBB4 (HER4) [HSA:2066] [KO:K05085]
  Pathway
hsa01521  EGFR tyrosine kinase inhibitor resistance
hsa04012  ErbB signaling pathway
hsa05200  Pathways in cancer
hsa05224  Breast cancer
  Network
nt06270  Breast cancer
Interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L01 ANTINEOPLASTIC AGENTS
   L01E PROTEIN KINASE INHIBITORS
    L01EH Human epidermal growth factor receptor 2 (HER2) tyrosine kinase inhibitors
     L01EH02 Neratinib
      D10898  Neratinib maleate <US>
USP drug classification [BR:br08302]
 Antineoplastics
  Molecular Target Inhibitors
   Neratinib
    D10898  Neratinib maleate
Drug groups [BR:br08330]
 Antineoplastic
  DG01918  Tyrosine kinase inhibitor
   DG01917  Receptor tyrosine kinase inhibitor
    DG03158  HER2 inhibitor
     DG02303  Neratinib
      D10898  Neratinib maleate
Drug classes [BR:br08332]
 Antineoplastic
  DG03158  HER2 inhibitor
   D10898  Neratinib maleate
Target-based classification of drugs [BR:br08310]
 Protein kinases
  Receptor tyrosine kinases (RTK)
   EGFR family
    EGFR
     D10898  Neratinib maleate <US>
    ERBB2* (HER2, CD340) [HSA_VAR:2064v1 2064v3]
     D10898  Neratinib maleate <US>
    ERBB4 (HER4)
     D10898  Neratinib maleate <US>
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D10898
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D10898
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D10898
Pharmacogenomic biomarkers [br08341.html]
 Somatic variations in targeted cancer therapies
  D10898
Drug groups [BR:br08330]
 Antineoplastic
  DG01918  Tyrosine kinase inhibitor
   DG01917  Receptor tyrosine kinase inhibitor
    DG03158  HER2 inhibitor
     DG02303  Neratinib
Other DBs
CAS: 915942-22-2
PubChem: 340650302
LinkDB
KCF data

ATOM        48
            1   C8y C    15.0537  -13.7228
            2   C8y C    15.0537  -12.3225
            3   C8x C    13.8635  -11.6224
            4   C8y C    12.6032  -12.3225
            5   C8y C    12.6032  -13.7228
            6   C8x C    13.8635  -14.4230
            7   N5x N    11.4130  -11.6224
            8   C8x C    10.2227  -12.3225
            9   C8y C    10.2227  -13.7228
            10  C8y C    11.4130  -14.4230
            11  N1b N    11.4130  -15.8233
            12  C8y C    12.6032  -16.5234
            13  C3b C     9.1025  -14.4230
            14  N3a N     7.8423  -15.1231
            15  C8x C    13.7935  -15.8233
            16  C8x C    15.0537  -16.5234
            17  C8y C    15.0537  -17.8537
            18  C8y C    13.8635  -18.5539
            19  C8x C    12.6032  -17.8537
            20  X   Cl   13.8635  -19.9542
            21  O2a O    16.2440  -18.5539
            22  C1b C    17.4342  -17.8537
            23  C8y C    18.6945  -18.5539
            24  N5x N    18.6945  -19.9542
            25  C8x C    19.8848  -20.6543
            26  C8x C    21.0750  -19.9542
            27  C8x C    21.0750  -18.5539
            28  C8x C    19.8848  -17.8537
            29  N1b N    16.2650  -14.4156
            30  O2a O    16.2673  -11.6284
            31  C1b C    16.2673  -10.2284
            32  C1a C    17.4626   -9.5380
            33  C5a C    17.4539  -13.7225
            34  C2b C    18.6501  -14.4066
            35  O5a O    17.4481  -12.3201
            36  C2b C    19.8313  -13.7181
            37  C1b C    21.0313  -14.4044
            38  N1c N    22.2107  -13.7171
            39  C1a C    23.4115  -14.4040
            40  C1a C    22.2051  -12.3201
            41  C2b C    27.4619  -18.0035
            42  C2b C    25.8507  -18.0035
            43  C6a C    28.1625  -19.1944
            44  C6a C    25.1502  -19.1944
            45  O6a O    27.4619  -20.3854
            46  O6a O    29.4935  -19.1944
            47  O6a O    23.8191  -19.1944
            48  O6a O    25.8507  -20.3854
BOND        50
            1     1   2 2
            2     2   3 1
            3     3   4 2
            4     4   5 1
            5     5   6 2
            6     1   6 1
            7     4   7 1
            8     7   8 2
            9     8   9 1
            10    9  10 2
            11    5  10 1
            12   10  11 1
            13   11  12 1
            14    9  13 1
            15   13  14 3
            16   12  15 2
            17   15  16 1
            18   16  17 2
            19   17  18 1
            20   18  19 2
            21   12  19 1
            22   18  20 1
            23   17  21 1
            24   21  22 1
            25   22  23 1
            26   23  24 2
            27   24  25 1
            28   25  26 2
            29   26  27 1
            30   27  28 2
            31   23  28 1
            32    1  29 1
            33    2  30 1
            34   30  31 1
            35   31  32 1
            36   29  33 1
            37   33  34 1
            38   33  35 2
            39   34  36 2
            40   36  37 1
            41   37  38 1
            42   38  39 1
            43   38  40 1
            44   41  42 2
            45   41  43 1
            46   42  44 1
            47   43  45 1
            48   43  46 2
            49   44  47 1
            50   44  48 2

» Japanese version   » Back

KEGG   DRUG: Tucatinib
Entry
D11141                      Drug                                   
Name
Tucatinib (USAN/INN);
Tukysa (TN)
Product
Formula
C26H24N8O2
Exact mass
480.2022
Mol weight
480.5212
Structure
Class
Antineoplastic
 DG01918  Tyrosine kinase inhibitor
  DG01917  Receptor tyrosine kinase inhibitor
   DG03158  HER2 inhibitor
Metabolizing enzyme substrate
 DG02918  CYP2C8 substrate
 DG01633  CYP3A/CYP3A4 substrate
Remark
ATC code: L01EH03
Chemical structure group: DG03240
Product (DG03240): D11141<US>
Efficacy
Antineoplastic, Receptor tyrosine kinase inhibitor
  Disease
Breast cancer (HER2 positive) [DS:H00031]
Target
ERBB2* (HER2, CD340) [HSA_VAR:2064v1] [HSA:2064] [KO:K05083]
ERBB3 (HER3) [HSA:2065] [KO:K05084]
  Pathway
hsa04010  MAPK signaling pathway
hsa04012  ErbB signaling pathway
hsa04151  PI3K-Akt signaling pathway
hsa05200  Pathways in cancer
hsa05224  Breast cancer
  Network
nt06270  Breast cancer
Metabolism
Enzyme: CYP2C8 [HSA:1558]; CYP3A [HSA:1576 1577 1551]
Interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L01 ANTINEOPLASTIC AGENTS
   L01E PROTEIN KINASE INHIBITORS
    L01EH Human epidermal growth factor receptor 2 (HER2) tyrosine kinase inhibitors
     L01EH03 Tucatinib
      D11141  Tucatinib (USAN/INN) <US>
USP drug classification [BR:br08302]
 Antineoplastics
  Molecular Target Inhibitors
   Tucatinib
    D11141  Tucatinib (USAN/INN)
Drug groups [BR:br08330]
 Antineoplastic
  DG01918  Tyrosine kinase inhibitor
   DG01917  Receptor tyrosine kinase inhibitor
    DG03158  HER2 inhibitor
     DG03240  Tucatinib
      D11141  Tucatinib
 Metabolizing enzyme substrate
  DG02918  CYP2C8 substrate
   DG03240  Tucatinib
    D11141  Tucatinib
  DG01633  CYP3A/CYP3A4 substrate
   DG03240  Tucatinib
    D11141  Tucatinib
Drug classes [BR:br08332]
 Antineoplastic
  DG03158  HER2 inhibitor
   D11141  Tucatinib
Target-based classification of drugs [BR:br08310]
 Protein kinases
  Receptor tyrosine kinases (RTK)
   EGFR family
    ERBB2* (HER2, CD340) [HSA_VAR:2064v1]
     D11141  Tucatinib (USAN/INN) <US>
    ERBB3 (HER3)
     D11141  Tucatinib (USAN/INN) <US>
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D11141
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D11141
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D11141
Drug metabolizing enzymes and transporters [br08309.html]
 Drug metabolizing enzymes
  D11141
Pharmacogenomic biomarkers [br08341.html]
 Somatic variations in targeted cancer therapies
  D11141
Drug groups [BR:br08330]
 Antineoplastic
  DG01918  Tyrosine kinase inhibitor
   DG01917  Receptor tyrosine kinase inhibitor
    DG03158  HER2 inhibitor
     DG03240  Tucatinib
 Metabolizing enzyme substrate
  DG02918  CYP2C8 substrate
   DG03240  Tucatinib
  DG01633  CYP3A/CYP3A4 substrate
   DG03240  Tucatinib
Other DBs
CAS: 937263-43-9
PubChem: 376219065
LinkDB
KCF data

ATOM        36
            1   C8y C    24.3600  -13.7900
            2   C8y C    24.3600  -15.1900
            3   C8y C    23.1700  -15.8900
            4   N5x N    21.9100  -15.1900
            5   C8x C    21.9100  -13.7900
            6   N5x N    23.1700  -13.0900
            7   C8x C    25.5500  -13.0900
            8   C8x C    26.8100  -13.7900
            9   C8y C    26.8100  -15.1900
            10  C8x C    25.5500  -15.8900
            11  N1b N    28.0000  -15.8900
            12  C2y C    29.1900  -15.1900
            13  O2x O    29.1900  -13.7900
            14  C1x C    30.5200  -13.3000
            15  C1z C    31.3600  -14.4200
            16  N2x N    30.5900  -15.6100
            17  N1b N    23.1700  -17.2900
            18  C1a C    32.0600  -13.2300
            19  C1a C    32.3400  -15.4000
            20  C8y C    24.3853  -17.9851
            21  C8x C    24.3911  -19.3897
            22  C8x C    25.6064  -20.0847
            23  C8y C    26.8159  -19.3797
            24  C8y C    26.8101  -17.9751
            25  C8x C    25.5948  -17.2801
            26  C1a C    28.0131  -17.2740
            27  O2a O    28.0312  -20.0746
            28  C8y C    27.9674  -21.4906
            29  C8x C    26.7728  -22.1638
            30  C8x C    26.7582  -23.5637
            31  N4y N    27.9632  -24.2763
            32  C8y C    29.1578  -23.6032
            33  C8x C    29.1724  -22.2033
            34  N5x N    28.2343  -25.6205
            35  C8x C    29.5964  -25.7781
            36  N5x N    30.1671  -24.5313
BOND        41
            1     1   2 2
            2     2   3 1
            3     3   4 2
            4     4   5 1
            5     5   6 2
            6     1   6 1
            7     1   7 1
            8     7   8 2
            9     8   9 1
            10    9  10 2
            11    2  10 1
            12    9  11 1
            13   11  12 1
            14   12  13 1
            15   13  14 1
            16   14  15 1
            17   15  16 1
            18   12  16 2
            19    3  17 1
            20   15  18 1
            21   15  19 1
            22   17  20 1
            23   20  21 2
            24   21  22 1
            25   22  23 2
            26   23  24 1
            27   24  25 2
            28   20  25 1
            29   24  26 1
            30   23  27 1
            31   27  28 1
            32   28  29 1
            33   29  30 2
            34   30  31 1
            35   31  32 1
            36   32  33 1
            37   28  33 2
            38   31  34 1
            39   34  35 2
            40   35  36 1
            41   32  36 2

» Japanese version   » Back

KEGG   DRUG: Margetuximab
Entry
D10446                      Drug                                   
Name
Margetuximab (USAN/INN);
Margetuximab-cmkb;
Margenza (TN)
Product
Formula
C6484H10010N1726O2024S42
Exact mass
145782.1685
Mol weight
145871.938
Sequence
(Heavy chain)
QVQLQQSGPE LVKPGASLKL SCTASGFNIK DTYIHWVKQR PEQGLEWIGR IYPTNGYTRY
DPKFQDKATI TADTSSNTAY LQVSRLTSED TAVYYCSRWG GDGFYAMDYW GQGASVTVSS
ASTKGPSVFP LAPSSKSTSG GTAALGCLVK DYFPEPVTVS WNSGALTSGV HTFPAVLQSS
GLYSLSSVVT VPSSSLGTQT YICNVNHKPS NTKVDKRVEP KSCDKTHTCP PCPAPELVGG
PSVFLLPPKP KDTLMISRTP EVTCVVVDVS HEDPEVKFNW YVDGVEVHNA KTKPPEEQYN
STLRVVSVLT VLHQDWLNGK EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ VYTLPPSRDE
LTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPLV LDSDGSFFLY SKLTVDKSRW
QQGNVFSCSV MHEALHNHYT QKSLSLSPGK
(Light chain)
DIVMTQSHKF MSTSVGDRVS ITCKASQDVN TAVAWYQQKP GHSPKLLIYS ASFRYTGVPD
RFTGSRSGTD FTFTISSVQA EDLAVYYCQQ HYTTPPTFGG GTKVEIKRTV AAPSVFIFPP
SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT
LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC
(Disulfide bridge: H22-H96, H'22-H'96, L23-L88, L'23-L'88, L134-L194, L'134-L'194, H147-H203, H'147-H'203, H223-L214, H'223-L'214, H229-H'229, H232-H'232, H264-H324, H'264-H'324, H370-H428, H'370-H'428; Glycosylation site: Asn-H300, Asn-H'300)
  Type
Peptide
Class
Antineoplastic
 DG01918  Tyrosine kinase inhibitor
  DG01917  Receptor tyrosine kinase inhibitor
   DG03158  HER2 inhibitor
Remark
ATC code: L01FD06
Product: D10446<US>
Product (mixture): D12756<US>
Efficacy
Antineoplastic, Anti-HER2 antibody
  Disease
Breast cancer (HER2 positive) [DS:H00031]
  Type
Monoclonal antibody
Target
ERBB2* (HER2, CD340) [HSA_VAR:2064v1] [HSA:2064] [KO:K05083]
  Pathway
hsa04012  ErbB signaling pathway
hsa05200  Pathways in cancer
hsa05224  Breast cancer
  Network
nt06270  Breast cancer
Interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L01 ANTINEOPLASTIC AGENTS
   L01F MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
    L01FD HER2 (Human Epidermal Growth Factor Receptor 2) inhibitors
     L01FD06 Margetuximab
      D10446  Margetuximab (USAN/INN) <US>
USP drug classification [BR:br08302]
 Antineoplastics
  Monoclonal Antibody/Antibody-Drug Conjugate
   Margetuximab
    D10446  Margetuximab (USAN/INN)
Drug groups [BR:br08330]
 Antineoplastic
  DG01918  Tyrosine kinase inhibitor
   DG01917  Receptor tyrosine kinase inhibitor
    DG03158  HER2 inhibitor
     D10446  Margetuximab
Drug classes [BR:br08332]
 Antineoplastic
  DG03158  HER2 inhibitor
   D10446  Margetuximab
Target-based classification of drugs [BR:br08310]
 Protein kinases
  Receptor tyrosine kinases (RTK)
   EGFR family
    ERBB2* (HER2, CD340) [HSA_VAR:2064v1]
     D10446  Margetuximab (USAN/INN) <US>
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D10446
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D10446
Pharmacogenomic biomarkers [br08341.html]
 Somatic variations in targeted cancer therapies
  D10446
Other DBs
CAS: 1350624-75-7
PubChem: 172232539
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system